Deciphera Pharmaceuticals, Inc. DCPH
Set alert
25.59 +25.59 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 2.21B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -15.23
- Beta
- 0.18
- Short ratio
- 1.05
- Inst. own
- 72.03%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 10, 2024
- 50-d avg
- 21.67
- 200-d avg
- 15.94
- 1y target
- 27.52
YTD chart
Events in this range
- Feb 6, 2024Earnings: —; estimate -0.58; surprise —%
- May 10, 2024Earnings: —; estimate -0.55; surprise —%
Signals (33)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | May 17, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 29, 2024 | 2 years ago |
| RSI: Overbought | Apr 29, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 15, 2024 | 2 years ago |
| SMA: Bearish | Apr 11, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 10, 2024 | 2 years ago |
| SMA: Bullish | Apr 9, 2024 | 2 years ago |
| SMA: Bearish | Apr 2, 2024 | 2 years ago |
| SMA: Bullish | Mar 28, 2024 | 2 years ago |
| SMA: Bearish | Mar 22, 2024 | 2 years ago |
| SMA: Bullish | Mar 20, 2024 | 2 years ago |
| SMA: Bearish | Mar 18, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 12, 2024 | 2 years ago |
| SMA: Bullish | Feb 14, 2024 | 2 years ago |
| SMA: Bearish | Feb 13, 2024 | 2 years ago |
| SMA: Bullish | Feb 9, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 9, 2024 | 2 years ago |
| SMA: Bearish | Feb 7, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 7, 2024 | 2 years ago |
| SMA: Bullish | Feb 5, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 5, 2024 | 2 years ago |
| SMA: Bearish | Feb 2, 2024 | 2 years ago |
| SMA: Bullish | Feb 1, 2024 | 2 years ago |
| SMA: Bearish | Jan 30, 2024 | 2 years ago |
| SMA: Bullish | Jan 29, 2024 | 2 years ago |
| SMA: Bearish | Jan 26, 2024 | 2 years ago |
| SMA: Bullish | Jan 25, 2024 | 2 years ago |
| SMA: Bearish | Jan 24, 2024 | 2 years ago |
| SMA: Bullish | Jan 23, 2024 | 2 years ago |
| SMA: Bullish | Jan 22, 2024 | 2 years ago |
| SMA: Bearish | Jan 19, 2024 | 2 years ago |
| SMA: Bearish | Jan 18, 2024 | 2 years ago |
Key statistics
- Market cap
- 2.21B
- Enterprise value
- 1.97B
- Trailing P/E
- 0.00
- Forward P/E
- -15.23
- PEG ratio
- -0.62
- Price / sales
- 12.65
- Price / book
- 6.65
- EPS (TTM)
- -2.21
- Beta
- 0.18
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -108.86%
- Revenue (TTM)
- 174.91M
- Revenue growth
- 34.50%
- Free cash flow
- -80.09M
- Total cash
- 272.53M
- Total debt
- 25.02M
- Return on equity
- -50.37%
- Shares outstanding
- 86.48M
- Short % of float
- 6.33%
- 50-day average
- 21.67
- 200-day average
- 15.94
Analyst view
Consensus: hold
Hold
Price target (mean) 27.52 +7.5% upside
Now 25.59
- Target (low)
- 25.60
- Target (mean)
- 27.52
- Target (high)
- 30.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
May 10, 2024
Expected May 10, 2024. Consensus EPS estimate -0.51.
Financials — quick view
DCPH Revenue — quarterly 45.00M
DCPH Net income — quarterly -45.08M
DCPH EPS — quarterly -0.52
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 10, 2024 | Mar 1, 2024 | -0.55 | — | — | — |
| Feb 6, 2024 | Dec 1, 2023 | -0.58 | — | — | — |
| Oct 30, 2023 | Sep 1, 2023 | -0.60 | — | — | — |
| Aug 9, 2023 | Jun 1, 2023 | -0.62 | — | — | — |
| May 3, 2023 | Mar 1, 2023 | -0.60 | — | — | — |
| Feb 7, 2023 | Dec 1, 2022 | -0.57 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 9, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 9, 2023 | Stifel | up | Hold | Buy |
| Jun 4, 2023 | JMP Securities | reit | — | Market Outperform |
| May 3, 2023 | JMP Securities | reit | — | Market Outperform |
| Mar 14, 2023 | JMP Securities | reit | — | Market Outperform |
| Feb 7, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. As of June 11, 2024, Deciphera Pharmaceuticals, Inc. operates as a subsidiary of Ono Pharmaceutical Co., Ltd.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- deciphera.com
News
- Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Earnings Scheduled For February 6, 2024
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Tuesday
- Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
- Earnings Scheduled For August 9, 2023
- Earnings Scheduled For February 7, 2023
Your note
Sign in to keep a note on DCPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRIGHTSTARS ASSOCIATES, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 21, 2024 | 23,107,800 |
| DHANAK DASHYANT | Officer | Stock Award(Grant) | Jun 10, 2024 | 0 |
| FLYNN DANIEL LEE | Officer | Sale | Jun 15, 2023 | 378,613 |
| FRIEDMAN FRANKLIN STUART | Director | Purchase | Jun 7, 2023 | 10,000 |
| HOERTER STEVEN L | Chief Executive Officer | Stock Award(Grant) | Jun 10, 2024 | 0 |
| KELLY THOMAS P. | Chief Financial Officer | Sale | Jun 15, 2023 | 57,140 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 8.51% | 6,707,026 | 94.43M | Jun 29, 2023 |
| Blackrock Inc. | 6.94% | 5,467,999 | 76.99M | Jun 29, 2023 |
| Redmile Group, LLC | 6.19% | 4,878,566 | 68.69M | Jun 29, 2023 |
| Armistice Capital, LLC | 5.79% | 4,560,000 | 64.20M | Jun 29, 2023 |
| Vanguard Group Inc | 5.57% | 4,392,270 | 61.84M | Jun 29, 2023 |
| Braidwell LP | 4.63% | 3,646,419 | 51.34M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.47% | 1,947,744 | 27.35M | Aug 30, 2023 |
| Vanguard Total Stock Market Index Fund | 2.23% | 1,760,798 | 24.79M | Jun 29, 2023 |
| iShares Russell 2000 ETF | 1.52% | 1,194,319 | 16.77M | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 1.02% | 801,229 | 11.28M | Jun 29, 2023 |
| Vanguard Strategic Equity Fund | 0.95% | 747,816 | 10.53M | Jun 29, 2023 |
| College Retirement Equities Fund-Stock Account | 0.83% | 653,297 | 9.20M | Jun 29, 2023 |